This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Ventrus Completes Clinical Development Staffing

NEW YORK, Feb. 1, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced the completion of its clinical development staffing.

Ventrus has contracted Mohan Kabadi, Ph.D. as head of Pharmaceutical Product Development and Manufacturing. Dr. Kabadi will be responsible for the supply of commercial grade API and drug product for our products and for the development of the extended release forms of Diltiazem cream. Previously, Dr. Kabadi was at Bristol-Myers Squibb, Novartis, Pfizer, Faulding, and Roche. In the past 20 years, Dr. Kabadi has formulated, manufactured and successfully launched more than 25 ethical, generic, and specialty products. Currently, he serves as the President of American Association of Indian Pharmaceutical Scientists (AAiPS) and holds membership as well as active participation in AAPS and CRS.

Monil Shah has been employed as Vice President, Clinical Research and Development. Dr. Shah has a Doctorate in Pharmacy from Rutgers University and drug development experience from Novartis, Amgen, Fibrogen, and most recently was Director of Clinical Strategic Planning at Celgene.

Celina Scholl has been employed as Clinical Project Manager. Ms. Scholl has drug development experience from Novartis and Merck Pharmaceuticals and most recently with GSK Biologics.

Christina S. DiArcangelo, CEO of Armonia Clinical Research, has been contracted to manage our outsourcing activities. Ms. DiArcangelo's expertise includes global outsourcing, project management, global contracting, site contracting, process development, and site and service provider budget development and negotiations. 

John Dietrich, formerly vice president of clinical operations of Ventrus and currently consulting with Ventrus, will continue consulting with Ventrus, and will manage our toxicology program and support our publication activities. Dr. Dietrich received his Ph.D. in Pharmacology and has been in the biopharmaceutical industry since 1979. Dr. Dietrich has held senior management positions in drug research and development for a number of biotech companies.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs